Clarivate Plc Reports Q2 2026 Results: Progress on Value Creation Plan Amid Life Sciences & Healthcare Divestiture
Key Highlights
- Q2 2026 revenues: \$587.3 million, down 5.5% year-over-year
- Organic revenues: Decreased 1.5%; organic subscription revenue up 0.7%
- Adjusted EBITDA: \$247.2 million (42.1% margin), compared to \$261.6 million (42.1% margin) in Q2 2025
- Net loss: \$268.6 million, driven by a \$221.7 million non-cash goodwill impairment charge
- Divestiture of Life Sciences & Healthcare segment to sharpen focus and enhance financial flexibility
- Debt reduction: Over \$200 million repaid in H1 2026
- 2026 outlook reaffirmed: ACV organic growth 2.0%-3.0%, adjusted EBITDA \$980M-\$1.04B, free cash flow \$365M-\$435M
Strategic & Financial Updates
Clarivate Plc (NYSE: CLVT) reported its second quarter 2026 results with a strong emphasis on executing its Value Creation Plan and strategic portfolio focus. The company highlighted continued organic recurring revenue expansion, cost discipline, AI innovation roadmap advancement, and significant deleveraging. Notably, the recently-announced divestiture of the Life Sciences & Healthcare (LS&H) segment is expected to create a more focused company and improve its financial profile.
Management Commentary
CEO Matti Shem Tov emphasized that the Value Creation Plan is driving meaningful progress, positioning Clarivate for accelerated organic growth. The CEO noted that the quarter saw expansion in organic recurring revenue, disciplined cost management, and a stronger balance sheet. The LS&H divestiture is expected to result in a higher recurring revenue mix and greater financial flexibility, setting a clear path for long-term shareholder value.
CFO Jonathan Collins added that the company expanded profit margin and reduced debt by more than \$200 million in H1 2026, underscoring strong free cash flow generation and opportunistic debt repurchases. Collins reaffirmed the full-year outlook and pointed to the resilience of Clarivate’s business model.
Detailed Financial Performance
Q2 2026 vs. Q2 2025
- Total revenues: \$587.3M (down from \$621.4M)
- Organic revenues: Decreased 1.5% (subscription up 0.7%, transactional down 15.7%)
- Net loss: \$268.6M (vs. \$72.0M loss in Q2 2025), primarily due to \$221.7M non-cash goodwill impairment
- Adjusted net income: \$123.1M (flat YoY)
- Adjusted EBITDA: \$247.2M (down 5.5% YoY)
- Free cash flow: \$44.0M (down from \$50.3M YoY)
H1 2026 vs. H1 2025
- Total revenues: \$1,172.8M (down 3.5%)
- Net loss: \$308.8M (vs. \$175.9M loss in H1 2025)
- Adjusted net income: \$242.4M (up 10.6%)
- Adjusted EBITDA: \$488.4M (down slightly from \$494.8M)
- Free cash flow: \$122.9M (down from \$160.6M)
Segment & Revenue Type Details
- Academia & Government: \$300.3M, down 5.7% YoY in Q2
- Intellectual Property: \$198.3M, down 2.1% YoY in Q2
- Life Sciences & Healthcare: \$88.7M, down 11.7% YoY in Q2 (segment to be divested)
- Organic ACV growth: 1.5% as of June 30, 2026
- Organic recurring revenue (subscription + re-occurring): Up 0.7% in Q2, offset by lower transactional revenue
Balance Sheet & Liquidity
- Cash & equivalents: \$217.7M as of June 30, 2026 (down from \$329.2M at year-end 2025)
- Total debt: \$4,251.5M (down \$218.4M from prior year, including repayment and repurchases)
- Share repurchases: \$18.1M in H1 2026
2026 Financial Outlook Reaffirmed (Assuming No Further M&A or Unanticipated Events)
- ACV Organic Growth: 2.0% to 3.0%
- Recurring Organic Revenue Growth: 0.75% to 2.25%
- Revenues (including discontinued operations): \$2.30B to \$2.42B
- Adjusted EBITDA: \$980M to \$1.04B (margin 42.0% to 43.5%)
- Adjusted Diluted EPS: \$0.70 to \$0.80 (based on ~650M shares)
- Free Cash Flow: \$365M to \$435M
The outlook includes important non-GAAP adjustments such as amortization, share-based compensation, impairments, restructuring, and transaction costs.
Other Shareholder-Relevant Information
- The LS&H segment divestiture is a critical, price-sensitive event. This move will significantly reshape the company’s portfolio, increase the recurring revenue mix, and may lead to further improvements in financial flexibility and shareholder value.
- Goodwill impairment charge of \$221.7M is a one-off non-cash event, but it substantially impacts reported net income for the quarter and half-year.
- Continued focus on deleveraging and cost discipline points to ongoing efforts to strengthen the company’s financial health and capacity for future growth investments.
- Share count: Slight reduction in outstanding shares due to repurchases.
- Potential risks highlighted include forward-looking statements and uncertainties related to macroeconomic volatility, strategic transaction execution, and AI-driven transformation.
Access to Further Information
Clarivate will host a webcast and conference call to discuss these results. Details are available on the company’s investor relations website.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties; actual results may differ materially from projections. Investors should review the full Clarivate SEC filings and consult their financial advisors before making investment decisions.
